International Stem Cell Corp. (ISCO) Milestone Advancement of Transplantable Human Cornea Program Captivates Market/Doctors
International Stem Cell Corp. has made bold progress developing ethically valid human parthenogenetic stem cell (hpSC) technology that allows for pluripotent stem cell creation from unfertilized eggs, and while this technology has incredibly broad application potential, it is the recent announcement by ISCO's R&D team regarding advancement of the company's transplantable human cornea program which currently captures the attention of both investors and ophthalmologists. The June 28 release by ISCO, detailing development by the company's R&D team of a new method for deriving corneal endothelium-like cells, largely validated prior data sets gathered from collaborator Sankara Nethralaya Eye Hospital in India,…